Cathelicidin is a pleiotropic host defense peptide secreted by epithelial and immune cells. Whether endogenous cathelicidin is protective against ulcerative colitis, however, is unclear. Here we sought to delineate the role of endogenous murine cathelicidin (mCRAMP) and the therapeutic efficacy of intrarectal administration of mCRAMP-encoding plasmid in ulcerative colitis using dextran sulfate sodium (DSS)-challenged cathelicidin-knockout (Cnlp À/À ) mice as a model. Cnlp À/À mice had more severe symptoms and mucosal disruption than the wild-type mice in response to DSS challenge. The tissue levels of interleukin-1b and tumor necrosis factor-a, myeloperoxidase activity and the number of apoptotic cells were increased in the colon of DSS-challenged Cnlp À/À mice. Moreover, mucus secretion and mucin gene expression were impaired in Cnlp À/À mice. All these abnormalities were reversed by the intrarectal administration of mCRAMP or mCRAMP-encoding plasmid. Taken together, endogenous cathelicidin may protect against ulcerative colitis through modulation of inflammation and mucus secretion.
INTRODUCTION
Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, are characterized by chronic inflammation and mucosal damage in the gastrointestinal tract. Although the etiology of IBDs is still poorly understood, accumulating evidence have suggested that interactions among environmental, genetic and immunoregulatory factors are responsible for the pathogenesis of the diseases. 1, 2 In this connection, the viscous mucus layer along the gastrointestinal tract, which is mainly composed of mucins and trefoil peptides, form a physical barrier protecting the underlying epithelium from mechanical, chemical, enzymatic and microbial damages. 3 During the active stage of ulcerative colitis, this layer was strongly disrupted and irregular with a 60 --70% decrease in its thickness. 4 This alteration was linked to depletion of recognizable goblet cells in the colonic epithelium. A recent MUC2-knockout mouse model has additionally revealed that animals with disrupted mucus lining suffered from more serious colitis, emphasizing the importance of mucus as a protective factor in colonic inflammation. 5 Therapies modulating the dysregulated immune responses and intervening the pro-inflammatory cascade have received much attention in the past decades. van Dullemen et al. 6 have demonstrated that neutralization of tumor necrosis factor-a (TNF-a) by an anti-TNF-a human/mouse chimeric monoclonal antibody could effectively improve colitis symptoms. The promising therapeutic effects of interleukin (IL)-10 administration have also been confirmed in mice. 7 In fact, several immunomodulatory agents like corticosteroids, 6-meracaptopruine, and azathioprine have been commonly used for treating patients with IBDs. However, the intolerable side-effects such as osteoporosis and cataracts make them unsuitable as long-term treatments. 8 The current IBD therapies mainly concentrate on relieving the inflammatory responses by bringing the disease into remission rather than preventing the relapse of the disease. More importantly, persistent inflammation in the colon may raise the risk for colorectal cancer. 9 A safer and more effective therapy is therefore urged for the treatment and prophylaxis of IBDs, and perhaps also for IBD-associated colorectal cancer in humans.
Cathelicidin is a family of endogenous antimicrobial peptides found on the surface of epithelial cells in the colon and stomach. 10 It inhibits the growth of most microorganisms including bacteria, fungi, certain parasites and viruses by membrane permeabilization. 11 Recent studies have illustrated its modulatory actions in innate immunity and inflammatory responses in addition to its antimicrobial activity. 12, 13 Cathelicidin can also prevent inflammatory responses triggered by lipopolysaccharide through the binding of its C-terminal with lipopolysaccharide. 14 In the human colon, cathelicidin is highly expressed in epithelial cells of the surface and upper crypts. Deeper crypt regions also have low-level expression of cathelicidin. 10 Its ability in modifying inflammatory response together with the relatively low toxicity may render cathelicidin an ideal implement in the treatment of IBDs. In fact, our previous findings have already hinted the feasibility of mouse cathelicidin (mouse cathelicidin-related antimicrobial peptide or mCRAMP) as a novel therapy for IBDs although the detailed mechanism of action remains obscured. Therefore, mCRAMPdeficient mice (Cnlp À/À ) were employed in the present study to clarify the protective actions of cathelicidin in ulcerative colitis. Moreover, the in vivo therapeutic effect of intrarectal administration of mCRAMP-encoding plasmid was evaluated. Improved knowledge may lead to further clinical studies in defining the therapeutic role of cathelicidin in IBDs.
RESULTS

Cnlp
À/À mice had higher disease activity during DSS-induced colitis Cnlp À/À mice were used in this study to specifically address the in vivo function of mCRAMP in gastrointestinal protection. Cnlp À/À mice were found to be more sensitive to dextran sulfate sodium (DSS)-induced colitis. Upon 5-day DSS treatment, Cnlp À/À mice developed more severe clinical symptoms, such as gross bleeding, diarrhea and weight loss as compared with the wildtype animals, which presented mild responses ( Table 1) . The disease activity index and crypt score representing disease severity were significantly higher in Cnlp À/À mice. To further examine the protective effects of mCRAMP on colitis, the synthetic peptide (5.0 mg kg À1 per day) or mCRAMP-expressing plasmid were administered intrarectally to mice according to the experimental setup (Figure 1) . A single dose (200 mg) of plasmid administration effectively upregulated the colonic expression of mCRAMP (Figure 2 ). This upregulation decreased gradually after 10 days (data not shown). Cnlp À/À mice suffered from more severe colitis whereas negligible symptoms were observed in the wild-type mice (Table 1) . Importantly, both mCRAMP supplements significantly ameliorated DSS-induced colitis in Cnlp À/À mice. mCRAMP-treated mice showed elevated body weights, reduced disease symptoms, colonic mucosal damage, disease activity index and crypt scores compared with colitis Cnlp À/À mice without any treatment.
Histologically, there were no morphological differences in the colon between untreated wild-type and Cnlp À/À mice. Although DSS exerted negligible influences on wild-type mice, DSS-treated Cnlp À/À mice showed marked signs of colonic inflammation and tissue destruction (Figure 3 ). These mice displayed accumulation of white blood cells, epithelial erosion and a loss of crypt architecture. These were further illustrated by the distinct alteration in crypt score (Table 1 ). In contrast, histological analysis of the sections from mCRAMP-treated Cnlp À/À mice with colitis showed obvious reduction of histological inflammation, and these animals were protected from DSS-induced mucosal injury with lesser epithelial distortion. mCRAMP supplements also increased crypt regeneration and restoration of colonic mucosa, which were comparable with the normal Cnlp À/À mice. Reduction of colonic length, a parameter of inflammation, correlated with the clinical symptoms. 15 Five-day DSS treatment showed no effect on the colonic length in wild-type mice (Figure 4a) . However, the colonic length in colitis Cnlp À/À mice without mCRAMP treatment was significantly shorter than that of normal Cnlp À/À mice and colitis wild-type mice. Both mCRAMP supplements effectively inhibited shortening of colon in DSS-challenged Cnlp À/À mice.
DSS-challenged
Cnlp À/À mice had higher colonic myeloperoxidase activity and cytokine levels Neutrophil infiltration into the colon was quantified by measuring the activity of myeloperoxidase (MPO). The colonic MPO activity in normal Cnlp À/À mice tended to be higher than the wild-type mice despite having no significance ( Figure 4b ). The activity substantially increased in colitis animals in which Cnlp À/À mice displayed much higher activity than the wild-type ones. In this regard, mCRAMP supplements significantly normalized the MPO activity in colitis Cnlp À/À mice to near those without DSS induction. The levels of two pro-inflammatory cytokines, IL-1b and TNF-a, in the colonic tissues from all tested animals were measured by enzymelinked immunosorbent assay. Five-day DSS treatment significantly raised the amount of both cytokines in wild-type and Cnlp À/À mice (Figures 4c and d) . In particular, the levels in Cnlp À/À mice increased to the greatest extent compared with the wild-type animals. This finding is similar to the disease severity in which Cnlp À/À mice displayed more severe colitis symptoms. These increases were effectively negated by both mCRAMP supplements in colitis Cnlp À/À mice. Colonic mCRAMP expression induced by the administration of mCRAMP-expressing plasmid. mCRAMP-expressing plasmid pcDNA3.1/mcramp (200 mg per mouse) was administered intrarectally to the wild-type mice. Colonic tissues were collected after 2 days. Western blot was performed on the colonic protein extracts (pooled from three mice from each group) to detect the expression of mCRAMP.
Cnlp À/À mice had impaired mucus secretion and mucin gene expression As shown by the periodic acid-Schiff staining, the thickness of the mucus-secreting layer in both wild-type and Cnlp À/À mice declined significantly during colitis (Figure 5a ). In particular, the thickness in colitis Cnlp À/À mice declined to the greatest extent, À39% as compared with the normal Cnlp À/À mice. Intrarectal supplements of mCRAMP during DSS feeding markedly increased the thickness of the mucus-secreting layer. The colonic gene expressions of MUC1, MUC2, MUC3 and MUC4, the building blocks of mucus, were monitored and compared among groups using real-time PCR. The results were consistent with our previous report and were summarized in Figures 5b --e. All detected mucin genes decreased markedly during inflammation in wild-type and
Cnlp
À/À mice. Especially, the gene expression in Cnlp À/À mice was downregulated to the greatest extent. mCRAMP supplements significantly reversed the downregulated expression during inflammation.
Apoptotic cell number was higher in DSS-challenged Cnlp À/À mice
The terminal deoxynucleotidyl transferase dUTP nick-end labeling staining showed that the number of apoptotic cells increased significantly in both types of mice during inflammation ( Figure 6 ). In particular, the increase in the Cnlp À/À mice was much higher than that in the wild-type animals. mCRAMP supplement substantially reduced the number of apoptotic cells back to the basal level. À/À mice. Colonic tissues from mice with different DSS and mCRAMP treatment were fixed in 10% formalin. Sections (5 mm) were prepared and stained with hematoxylin --eosin (original magnification Â 100). Five-day DSS treatment entirely destroyed mucosal structure and reduced crypt formation in Cnlp À/À mice. Peptide or plasmid treatment preserved the mucosal crypt structure.
DISCUSSION
Endogenous antimicrobial peptides, such as b-defensin and cathelicidin, serve essential functions in the innate immune system in mammals. Cathelicidin in particular received much attention in past decades because of its pronounced influences on inflammation and wound healing. 13 We have previously demonstrated that intrarectal administration of synthetic mouse cathelicidin could effectively mitigate experimental colitis in a murine model. 16 A recent study by Koon et al. 17 also demonstrated that endogenous or E. coli DNA-induced cathelicidin could protect against experimental colitis in mice through activation of toll-like receptor 9-extracellular signal-regulated kinases signaling. In fact, cathelicidin expression is found to be upregulated in inflamed and non-inflamed mucosa of patients with ulcerative colitis. 18 mCRAMP expression is also known to be induced in DSS model of colitis. 17 These findings indicate that cathelicidin is an autoregulatory protective factor for preserving mucosal integrity. To fully address the functions of cathelicidin in gastrointestinal protection, mice with targeted deletion of Cnlp, the gene encoding the mCRAMP, and wild-type mice were evaluated for the symptomatic and histopathologic manifestations of colitis induced by DSS. The protective action of exogenous mCRAMP and mCRAMP gene transfer via an intrarectal route were also investigated in the current study.
Under normal conditions, Cnlp À/À mice tended to have shorter colon length, higher MPO activity, and thinner mucus-secreting layer than the wild-type mice although no significant differences were detected. These may partially explain the increased susceptibility towards DSS-induced colitis in the Cnlp À/À mice. Histological findings indicated that deletion of Cnlp resulted in no distinct change in epithelial architecture in colon (Figure 3) . The efficiency of intrarectal mCRAMP peptide therapy has been demonstrated in our previous study. 16 Nevertheless, the high production cost of peptide confined the clinical application of cathelicidin in human IBDs. To overcome this problem, we have employed a novel gene delivery strategy reported by Kanbe et al. 19 to upregulate mCRAMP expression in colonic epithelium. A mCRAMP-expressing plasmid was constructed and intrarectal administration of the plasmid could successfully boost the protein expression of mCRAMP in colon up to 10 days (Figure 2) . Results here strengthen the idea that intrarectal administration of naked DNA could be an effective therapy for human ulcerative colitis.
The present study emphasizes the importance of cathelicidin in gastrointestinal protection. Cnlp À/À mice had significantly higher susceptibility towards DSS-induced colitis. The animals were characterized by the presence of inflammation in the colon indicated by significant weight loss, diarrhea, gross bleeding, crypt destruction, mucosal damage and epithelial erosions. In contrast, wild-type mice only displayed mild responses after the 5-day DSS induction. It is interesting to note that both mCRAMP supplements could effectively protect Cnlp À/À mice from DSS-associated mucosal injury, with mild colitis symptoms and less epithelial destruction. mCRAMP treatment alleviated neutrophil infiltration in the inflammatory colon tissues, as shown by a substantial drop in colonic MPO activity (Figure 4 ). This would partly explain the protective role of mCRAMP in inflammation. In addition, apoptosis is one of the ulcerogenic process in the gastrointestinal mucosa 20 and upsetting this process in the colonic mucosa may relate to the pathogenesis of IBDs. In this connection, mCRAMP may prevent DSS-induced colitis by inhibiting apoptosis in the colonic tissues ( Figure 6 ).
In line with our previous report, 16 the effect of mCRAMP on the thickness of mucus-secreting layer in the colon has been demonstrated. Cnlp À/À mice showed significant decline in the thickness of mucus-secreting layer after colitis induction and, importantly, mCRAMP supplements preserved the mucus-secreting layer ( Figure 5 ). Results from real-time PCR suggest that cathelicidin stimulates mucus synthesis in the colonic mucosa by upregulating the mRNA expression of mucins, including MUC1, MUC2, MUC3 and MUC4. However, tissue fixation in Carnoy's solution would be required to examine the direct effect of cathelicidin on mucus thickness. Increasing evidence suggests that abnormal mucus secretion is a pathogenic hallmark of IBD. Apparent decline in the colonic mucus thickness was associated with the initiation or perpetuation of ulcerative colitis. 21 During the active stage of ulcerative colitis, the mucus layer is strongly disrupted and discontinuous with a 60--70% in thickness. 4 A recent MUC2-knockout mouse model has further confirmed that disruption in mucus synthesis could exacerbate experimental colitis induced by DSS. 5 These findings substantiate the idea that cathelicidin may serve as a therapeutic tool for treating ulcerative colitis by raising the mucin gene expression and enhancing mucus synthesis in the colonic mucosa, which was found to be disturbed in ulcerative colitis patients.
It is established that pro-inflammatory cytokines have a pivotal role in the inflammation of the intestinal mucosa. 1, 22, 23 Elevated levels of various cytokines have been detected in mucosal tissue samples from the patients with IBDs. 23 They contribute to the increased migration of neutrophils and monocytes into the lesion of IBDs and to the activation of inflammatory cells. Particularly, IL-1b, IL-6 and TNF-a have been proposed to take part in the pathogenesis of IBDs. 2, 24 These cytokines result in the amplification of the inflammatory cascade and secretion of more inflammatory mediators, destructive enzymes and free radicals that cause tissue injury. 25 Analysis of colonic tissues of wild-type and Cnlp À/À mice showed remarkable increases in the level of IL-1b and TNF-a during DSS-induced colitis. Most notably, the increases in Cnlp À/À mice were about 40 --50% higher than the wild-type mice. Consistent with the above observation, mCRAMP supplements could effectively eliminate the alterations in colonic cytokine levels. Real-time PCR data showed no observable changes in IL-6 level in the mice (data not shown). In conjunction, these results support our hypothesis that cathelicidin could relieve intestinal inflammation through modulating the secretion of proinflammatory cytokines. In addition to its modulatory effects on cytokine production and mucin gene expression, cathelicidin possesses the ability to promote the direct elimination of pathogenic microbes by serving as a 'natural antibiotic'. 13 As DSS-induced colitis allows easy bacterial access to the damaged epithelium, it is possible that cathelicidin may protect against colitis through its antimicrobial action.
The findings presented so far provide direct evidence on the protective role of cathelicidin against colonic inflammation. Cnlp À/À mice displayed increased susceptibility towards DSS-induced colitis, and cathelicidin supplement or gene therapy could efficiently alleviate intestinal inflammation. mCRAMP-treated colitis mice showed more mild inflammatory responses with reduced clinical symptoms and lesser mucosal damage. Apart from its inflammation-modulatory action in colonic mucosa, we further demonstrated the stimulatory effect of cathelicidin on mucus production. Taken together, cathelicidin may prevent colitis development by blocking the deleterious inflammation cascade of cytokines and by promoting mucus secretion.
MATERIALS AND METHODS Animals
129/VJ wild-type and cathelicidin-knockout (Cnlp À/À ) mice were produced as previously described. 26 Male (6 --8-week old) mice were used in the following experiments. They were allowed free access to standard laboratory chow (Ralston Purina, Chicago, IL, USA) and tap water. All animals were housed in an air-conditioned room with controlled temperature (22±1 1C), humidity (65 --70%), and day/night cycle (12:12-h light:dark). The present study was approved by the University of Hong Kong Committee on the Use of Live Animals for Teaching and Research.
Induction of colitis
Acute colitis was induced in mice by giving 3% DSS (molecular weight, 36 --50 kDa; ICN Pharmaceuticals, Costa Mesa, CA, USA) as previously described. 27 The 3% DSS was given in the drinking water for 5 days (from day 0 to day 5). Mice receiving tap water throughout the experiment were used as a normal control group. mCRAMP treatment The mice were divided into two major groups: a wild-type group and a Cnlp À/À group. Each group contained a normal control group that received tap water alone and a disease group that received 3% DSS. To evaluate the protective effects of mCRAMP on ulcerative in mice, the Cnlp À/À mice with colitis were further divided into three sub-groups: one without any treatment and two with mCRAMP supplements. The full length of the mature mCRAMP was purchased from Innovagen (Lund, Sweden), and the peptide was dissolved in phosphate-buffered saline for rectal administration. The peptide, 5 mg kg À1 , was administered daily as previously described. 16 The disease-control mice received equal volume of phosphate-buffered saline intrarectally.
Plasmid treatment
Effective gene transfer to colonic epithelium was achieved according to the method reported by Kanbe et al. 19 A mCRAMP-expressing plasmid, pcDNA3.1/mcramp, was constructed by cloning the full-length mCRAMP complementary DNA into pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). Target gene expression was controlled under a cytomegalovirus promoter. The same plasmid without mCRAMP insert was used as negative control. All plasmids were amplified in DH5a Escherichia coli-competent cells (Invitrogen) and purified with an endo-free plasmid mega-kit (Qiagen, Valencia, CA, USA). Two hundred microgram of plasmid DNA was administrated intrarectally at the beginning of colitis induction (that is, day 0). Mice were kept in an inverted position for 1 min after administration to prevent leakage of the plasmid from the anus.
Clinical symptom scoring
For all animals, body weight, stool consistency and presence of gross bleeding were recorded. After colon removal, the length of colon from colo --cecal junction to the anal verge was measured. Disease activity index was calculated according to the method described by Cooper et al. 28 Briefly, body weight loss, stool consistency and gross bleeding were scored from 0 to 4, and disease activity index is the combined score divided by 3.
Morphologic analysis
Colonic sections from all mice were fixed in 10% formalin solution (pH 7.4). Histological examination was carried out with hematoxylin --eosin staining in paraffin sections after longitudinal sections of the colon were made. The height of crypt, which indicates the integrity of colon, was measured as previously described. 29 
Measurement of cytokines in colonic tissues
The amount of two cytokines, IL-1b and TNF-a, in the colonic tissues was measured using commercially available enzyme-linked immunosorbent assay kits (Quantikine Mouse IL-1b/IL-1F2 and TNF-a/TNFSF1A Immunoassays by R&D Systems, Minneapolis, MN, USA), according to the manufacturer's protocols. Minimum detectable concentrations were determined by the manufacturer as 3 pg ml À1 and 5.1 pg ml À1 , respectively. All samples were run in duplicate and the levels of cytokine produced in the colon were calculated as the amount per mg of protein.
MPO activity in the colonic tissues
Colonic MPO activity was measured as described previously. 29 In short, colon tissue was homogenized in an ice-cold 50 mmol ml À1 phosphatebuffered saline (pH 6.0) solution with 0.5% hexa-decyl-trimethyl-ammonium bromide. The homogenate was freeze-thawed three times followed by repeated sonication for 60 s each and was centrifuged for 20 min at 14 000 r.p.m. at 4 1C. The activity of supernatant was determined spectrophotometrically at 450 nm. The final value was expressed as enzyme units per mg of protein.
Assessment of thickness of mucus-secreting layer
Colonic samples were fixed in formalin overnight and embedded in paraffin. Five micron sections were made and stained with the periodic acid-Schiff technique as described previously. 30 The sections were counterstained with Harris hematoxylin and mounted in Permount (Fisher Scientific, Philadelphia, PA, USA). The mucus-containing cells were stained purple --red. The thickness of the mucus-secreting layer was measured perpendicular to the mucosal surface from the edge of the epithelium to the outermost part of the mucus layer under an image analyzer (Q500IW, Leica Image Systems, Cambridge, UK) at Â 100 magnification. Three measurements were taken per field and approximately six consecutive fields per section were measured, and results were expressed as the ratio of the thickness of the mucus-secreting layer to the thickness of the total mucosa.
Quantitative analysis of mucin gene expression
The total RNA was isolated from mouse colonic tissues with TRIzol reagent (Invitrogen) according to the manufacturer's instructions. A total of 2.5 mg extracted RNA was used as the template for complementary DNA synthesis using the Thermoscript reverse transcription-PCR system (Invitrogen). Quantitative real-time PCR was performed for MUC1, MUC2, MUC3, MUC4 and b-actin using the primer pairs as published previously. 16 The complementary DNA was amplified using iQ SYBR Green supermix (Bio-Rad Laboratories, Hercules, CA, USA) on the iCycler thermal cycler (Bio-Rad), programmed at 95 1C for 10 min, then 40 cycles of denaturation (95 1C for 15 s), annealing (59 1C for 15 s) and elongation (72 1C for 15 s). The amplification results were detected and analyzed using the iQ5 real-time PCR detection system. The gene signals were standardized
